PDE-5 inhibitor use shows no effect on BPH therapy outcomes


On-demand use of a phosphodiesterase type-5 inhibitor did not affect prostatic or urinary outcomes of therapy for BPH, a post hoc analysis of a large randomized trial showed.

Related Videos
Dr. Kyle A. Richards in an interview with Urology Times
Expert on OAB
Experts on OAB
Expert on OAB
3d rendered illustration - bladder cancer | Image Credit: © SciePro - stock.adobe.com
stethoscope on laptop keyboard
Experts on prostate cancer
Randie White, MD, answers a question during a Zoom video interview
Related Content
© 2023 MJH Life Sciences

All rights reserved.